Form 4 for OKUR OnKure Therapeutics, Inc.
Accepted 2025-12-23 00:00:00 ET · period of report 2025-12-22 · accession 0001692747-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-23 | 2025-12-22 | OKUR | Leverone Jason A. | CFO | S - Sale | $2.97 | -302 | 16.3K | -2% | -$896.94 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-12-22 | S | D | 302 | $2.97 | 16,301 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F4) Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025. (F3) Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |